BCL2L1 and neoplasm: Weeden et al. identified that triple BCL-XL, MCL-1, and FGFR inhibition resulted in regression of tumor volume and prolonged in vivo survival using patient-derived xenografts, thereby demonstrating the ability of BCL-XL and MCL-1 proteins to compensate for each other in lung SqCC 37.